GlycoMimetics has filed a patent for CD33 ligands that can be used to synthesize CD33 ligand-bearing carriers. These carriers can be linked to anti-cancer agents and used for treating and preventing diseases like acute myeloid leukemia (AML). The patent claim includes compounds of Formula (I). GlobalData’s report on GlycoMimetics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights GlycoMimetics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on GlycoMimetics, cancer treatment biomarkers was a key innovation area identified from patents. GlycoMimetics's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.

Cd33 ligands for cd33 ligand-bearing carriers with anti-cancer agents

Source: United States Patent and Trademark Office(USPTO). Credit: GlycoMimetics Inc

A recently filed patent (Publication Number: US20230167150A1) describes a range of compounds and processes for their synthesis. The patent claims cover various entities chosen from compounds of Formula (I). These entities have specific structural features, including substituents and functional groups, which are defined in the claims.

The compounds of Formula (I) have a wide range of possible substituents, including aryl groups, alkyl groups, hydroxyalkyl groups, and halo groups. The claims also specify that certain groups, such as R4 and R5, can be hydrogen or can join together to form an acetonide. Other substituents, such as R6 and R7, can be hydrogen or specific functional groups like acetyl or methyl.

The claims further describe the possible values for variables in the compounds, such as q, which can range from 1 to 4, or can be specifically 2 or 3. The claims also define the possible values for other variables, such as L1, V, X, Y, and Z, which can be specific chemical groups or bonds.

The patent claims also cover a process for making the compounds of Formula (II), prodrugs of these compounds, and pharmaceutically acceptable salts. This process involves reacting or associating the entities described in claim 1 with entities of Formula (III). The process can be carried out using various linker groups and carriers, such as nanoparticles, liposomes, and proteins.

Overall, the patent claims describe a range of compounds and a process for their synthesis. These compounds have specific structural features and substituents, and the process involves reacting or associating specific entities to form the desired compounds. The patent claims provide a detailed framework for the synthesis and potential applications of these compounds.

To know more about GlobalData’s detailed insights on GlycoMimetics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies